Halozyme Therapeutics, Inc. (HALO) Institutional Ownership

Ownership Summary

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has 620 institutional investors that have filed 13F reports for the period ending March 2026.

• These investors held 102.5% of outstanding shares in March 2026, down from 104.9% in December 2025.
• Their total shares held in HALO increased 10.68% quarter over quarter, and separately, investors owning Halozyme Therapeutics increased 12.73% from a year ago.
• During the quarter, 327 of these 620 funds increased positions in HALO, 209 reduced exposure, and 84 held steady.
• The aggregate institutional position in Halozyme Therapeutics amounted to 121.09Mn shares as of March 2026, up by 11.68Mn shares quarter on quarter, and down 12.05Mn shares year over year.
• As of March 31, 2026, BlackRock, Inc. held the largest stake in Halozyme Therapeutics with 13.27Mn shares, accounting for 11.23% of total shares outstanding.
• The largest buyers of Halozyme Therapeutics for the quarter ending March 2026 were VANGUARD CAPITAL MANAGEMENT LLC (5.27Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (5.25Mn), Boston Partners (2.2Mn), Janus Henderson Group Plc (1.6Mn), TWO SIGMA INVESTMENTS, LP (867.59K).
• Top sellers of HALO stock for the quarter ending March 2026 included ARROWSTREET CAPITAL, LIMITED PARTNERSHIP (1.3Mn), FULLER & THALER ASSET MANAGEMENT, INC. (1.29Mn), MILLENNIUM MANAGEMENT LLC (992.66K), Empowered Funds, LLC (637.36K), NATIXIS (466.29K).
• According to Business Quant data, leading holders of HALO for March 2026 are BlackRock, Inc. (13.27Mn), VANGUARD CAPITAL MANAGEMENT LLC (5.27Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (5.25Mn), State Street Corp (4.94Mn), Invesco Ltd. (4.01Mn), Bank Of America Corp /De/ (2.91Mn), Boston Partners (2.68Mn), Morgan Stanley (2.56Mn), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (2.53Mn), GEODE CAPITAL MANAGEMENT, LLC (2.51Mn).